Keyword → AMGN

FDA's Vinay Prasad to Exit Biologics Post in April, Sending Biotech Stocks Sharply Higher

The announced departure of Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, triggered a significant rally in biotech equities Monday, with uniQure surging more than 31% in premarket trading. Investors interpreted the news as a signal that the agency may adopt a more predictable and industry-friendly regulatory posture for vaccines, gene therapies, and rare disease treatments.

ADP Report: Private Payrolls Rise 63,000 in February, Beating Estimates but Revealing Narrow Job Growth

The ADP National Employment Report released Wednesday showed U.S. private employers added 63,000 jobs in February, topping consensus estimates of 50,000 and improving from a downwardly revised 11,000 in January. However, gains were concentrated almost entirely in construction and education and health services, with professional and business services shedding 30,000 positions, raising questions about underlying labor market breadth ahead of Friday's official nonfarm payrolls report.

Gilead Sciences to Acquire Arcellx for $7.8 Billion in Major CAR-T Cell Therapy Bet

Gilead Sciences announced Monday it will acquire Arcellx for $115 per share in cash plus a contingent value right of $5 per share, representing an implied equity value of $7.8 billion and an 87% premium to Arcellx's Friday closing price. The deal centers on anito-cel, an investigational BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma that has already received FDA acceptance of its Biologics License Application, with a regulatory decision expected by December 23, 2026.

OPKO Health Schedules Q4 Earnings Report, Shares React to Upcoming Guidance

OPKO Health announced plans to release its fourth-quarter and full-year 2025 financial results later this month, expected to include commentary on future revenue and profitability. The upcoming earnings call could influence sentiment among healthcare and biotech investors amid broader market volatility.